Recent Updates
Recently added Catalysts
PROF Positive Sentiment

Profound Medical Receives U.S. FDA 510(k) Clearance for TULSA-PRO® Thermal Boost

Monday, February 19, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Profound Medical has announced that it has received 510(k) clearance from the U.S. FDA for its TULSA-PRO® Thermal Boost system. This clearance allows the company to market the device, which is expected to improve treatment options for patients. The approval represents a significant advancement in the company's product offerings.
Price reaction · baseline $8.5 (2024-02-16 close) · clean, no other PROF news in the window
day 0 close · peak
-2.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Profound Medical received FDA clearance for TULSA-PRO®.
  • This approval may enhance treatment options for patients.
  • The clearance signifies a step forward in medical technology.

Full Press Release Details

Latest News

Company Overview

Stock Snapshot

Email Alerts

Sign up today and receive company updates straight to your inbox.

Company

Profound Medical Corp. 2400 Skymark Avenue Unit 6 Mississauga, ON L4W 5K5 Canada

Transfer Agent

Computershare Trust Company, N.A. (U.S.) 118 Fernwood Avenue Edison, NJ 08837 United States of America T: 732-417-2700
TSX Trust Company (Canada) 301-100 Adelaide Street West Toronto, ON M5H 4H1 Canada T: 866-600-5869

Connect With Us

• X
• Facebook
• LinkedIn
• YouTube

Frequently Asked Questions

What is TULSA-PRO®?

TULSA-PRO® is a thermal boost system developed by Profound Medical.

What does FDA 510(k) clearance mean?

FDA 510(k) clearance indicates that a medical device is safe and effective for its intended use.

How does TULSA-PRO® improve treatment options?

TULSA-PRO® enhances treatment options by providing advanced thermal therapy.

Who is Profound Medical?

Profound Medical is a company focused on innovative medical technologies.

ShareAdd on Google
Tags: PROF Viatris Investor Conferences Healthcare Profound Medical TULSA-PRO FDA clearance thermal boost medical technology
Last updated: Feb 19, 2024

Biotech snapshot

Cash runway
$38M liquidity · $4M/mo burn
~10 mo
Medium dilution risk